GLP-1 programs
GLP-1 Marketing That Wins Patients Under the 2026 Rules
We market the supervised program, not the molecule. Compliant ads, provider-led creative and retention built in, so patients stay and your ad accounts stay live.
The short answer
GLP-1 marketing is the work of attracting and keeping patients for a provider-supervised weight program that may include GLP-1 medications, without breaking FDA, ad platform or state rules. In 2026, what works is selling the program and the provider care, describing approved and compounded options accurately, naming the compounding pharmacy where required, avoiding outcome promises, and building retention in from day one.
Written by Justin Ingram, founder of ModFX Media20+ years in medical sales, built and ran seven clinics, and has built telehealth funnels and brands since COVID.Last updated October 8, 2026Results vary by offer, state mix, budget and execution. Past results do not guarantee future results.
Why is GLP-1 the most competitive category in telehealth?
Almost every telehealth platform has added a weight program. That means crowded ad auctions, look-alike landing pages, and patients who have seen the same offer ten times this week. Regulators also watch this category more closely than any other in telehealth.
So GLP-1 marketing only works when three things work at once:
Miss one and the other two stop paying off. A strong offer with a noncompliant ad loses the account. Great creative for a program patients quit in month two never earns back its cost.
Offer
What the patient actually gets: a licensed provider, a clear process, follow-up and support between refills. It has to be worth staying for, not just signing up for.
Creative
Provider-led, education-first ads that earn trust fast and still pass review.
Compliance
Every claim on the ad, page, checkout and label checked before launch.
The rules changed in 2026
In 2026 the FDA sent two large rounds of warning letters about how telehealth companies market compounded GLP-1s. Both target marketing language, not just medications.
| Date | What happened | What the FDA flagged |
|---|---|---|
| 3 March 2026 | 30 warning letters to telehealth companies | Compounded products presented as effectively the same as FDA-approved drugs. Private-label branding that obscured who actually made the medication. |
| 16 June 2026 | 25 more warning letters | Labels implying the seller was the compounder. Claims that compounded drugs were FDA-approved. Pharmacies described as “FDA-approved” or “FDA-licensed.” |
Sources: Venable on the March 2026 letters and McDermott on the June 2026 letters.
The FDA is reading the whole funnel: ads, landing pages, labels and checkout. Your marketing is now part of your compliance exposure, and so is whoever writes it. The hiring question is no longer “who can get me leads.” It’s “who can get me patients without putting my brand in the next round of letters.”
This section is educational, not legal advice. Rules vary by state, so work with healthcare counsel on your program.
How we market GLP-1 programs
We sell the supervised program, not the molecule
Patients don’t buy a molecule. They buy a plan they can stick to: a licensed provider who reviews their history, someone to message when something feels off, and support between refills. That’s what our ads, pages and emails sell. Medication is prescribed only when a provider decides it fits.
We describe approved and compounded options accurately, never as equivalent
Some programs offer FDA-approved brand-name medications. Some offer compounded medications, prepared by a 503A compounding pharmacy (a state-licensed pharmacy that prepares medications for individual patient prescriptions). Many offer both.
We describe each for what it is. Compounded medications are not FDA-approved. We never call them generic, the same as, or equivalent to Ozempic, Wegovy, Mounjaro or Zepbound. That rule covers semaglutide marketing and tirzepatide marketing alike.
We identify the compounder where required
Private-label branding that hid the real maker was a central FDA complaint in March 2026. Where state rules or your counsel require it, your site, labels and patient materials name the pharmacy that compounds the medication.
We make no outcome promises
No pound counts, no timelines, no before-and-after bodies. A real patient’s story runs only with written consent, labeled as one person’s experience, alongside typical-experience language. Your providers set clinical claims. Your counsel signs off before launch.
Provider-led creative
The most trusted face in a GLP-1 ad is a provider explaining how the program works. We build doctor and provider pages that give your ads credibility, and script short videos your providers can record in an afternoon. We also produce AI-assisted video and creator-style content. AI content is never presented as a real patient testimonial.
Account hygiene and LegitScript
GLP-1 ads get reviewed harder than almost any category. We set accounts up to pass: verified business and domain, landing pages that match the ad, no before-and-after images, no hooks about a person’s body, and 18+ age targeting. We also prepare you for LegitScript, the third-party certification Google and Meta check before they let a telehealth brand advertise prescription treatments.
Payment processors watch your funnel too, and they often drop telehealth merchants over chargebacks. The usual cause is a patient who didn’t understand a recurring charge. Clear checkout copy and a reminder before each renewal protect your merchant account as much as your ad account.
Retention is built in, because months 3 to 6 decide the economics
In our accounts, cold new-patient CAC (what it costs to acquire one paying patient) typically runs $150 to $350, and mature campaigns often land around $90 to $170. Patient lifetime value in these programs is often $2,000 to $3,000 or more. That gap only closes if the patient stays.
A patient who leaves after month one rarely pays back what it cost to win them. Most lifetime value sits after the first few refills, so months 3 to 6 decide whether a GLP-1 program makes money.
Drop-off clusters at predictable moments: the first refill, the first plateau, and the first side-effect question that waits too long for an answer. We build for those moments:
- Refill reminders and check-ins timed to each patient’s cycle
- Fast routes to a provider through secure messaging
- Progress tracking inside your branded telehealth app
- Win-back flows for patients who pause
Results vary by offer, state mix, budget and execution. Past results do not guarantee future results. See more in our telehealth marketing case studies.
From the field
When I ran clinics, the patients who paid the bills were the ones who stayed, not the ones who walked in the door. GLP-1 telehealth is the same business on a faster clock. I’ve watched brands celebrate a low acquisition cost, then lose most of those patients before month three. The ad account didn’t fail them. The follow-up did. So I judge every GLP-1 launch on two numbers: what a patient costs to acquire, and how many are still with you at month six. If we can’t move the second, I don’t want to scale the first.
Justin Ingram
What we never say, and what we say instead
These are the claim patterns we screen for in every ad, page, email and label. Your providers and counsel make the final call on exact wording.
| We never say or imply | What we do instead |
|---|---|
| A compounded medication is the “same as,” “generic,” or “equivalent to” Ozempic, Wegovy, Mounjaro or Zepbound | Describe the program and provider oversight, and state that compounded medications are not FDA-approved |
| An “FDA-approved” or “FDA-licensed” pharmacy | “State-licensed pharmacy,” with the compounder named where required |
| Branding that suggests your company makes the medication | Name the compounding pharmacy where required |
| Weight-loss promises, pound counts or timelines | Typical-experience language, with patient stories only with written consent |
| Approved-drug study results presented as proof for a compounded product | Explain what the provider evaluates and monitors |
| Before-and-after bodies or hooks that shame a person’s weight | Provider-led education and the support patients actually get |
| “No doctor needed” or “approved in minutes” | “A licensed provider reviews your health history and decides if treatment is right for you” |
GLP-1 advertising channels that work now
How we use each channel in 2026:
| Channel | What it does well | What it requires |
|---|---|---|
| Meta (Facebook and Instagram) | Reach and demand with provider-led video | LegitScript certification and Meta approval to promote prescription treatment, 18+ targeting, no body-focused hooks |
| Google Search | Capturing people already searching | LegitScript certification for prescription drug terms, pages that match the ad |
| Google Shopping | High-intent listings | LegitScript certification and a clean product feed |
| SEO | Demand that compounds over time | Treatment and goal pages with clinical review. Meaningful organic traction typically takes 3 to 4 months. |
| Email and SMS | Retention, refills, win-back | A HIPAA-compliant CRM (we build on GoHighLevel), consent for texts, no health details in subject lines |
Our SEO pages are built to be read, understood, and cited by Google, ChatGPT and Perplexity. Every channel feeds the same follow-up: ModBot AI, our AI voice agent, calls new leads and books them, and Mod Chat AI answers questions on your site and books visits.
Who our GLP-1 marketing is for
Planning other provider-led therapies? See peptide marketing. For marketing for GLP-1s alongside every other category, start with our telehealth marketing guide or the telehealth launch and marketing hub.
DTC weight loss brands
Founders launching or scaling a GLP-1 brand who need patients, not traffic, with every claim checked before it runs.
Med spas and clinics adding a virtual GLP-1 program
You already treat weight loss patients in person. A virtual program reaches people who can’t reach your office. For the in-clinic side, see weight loss clinic marketing.
Medical practices
Primary care, women’s health and other practices that already manage weight and want a program patients can follow from home.
“I already have an agency.”
Good. Ask them three things. Who checks every claim against the 2026 warning letters? What’s the plan for months 3 to 6? Are your ad accounts set up for LegitScript-certified prescription advertising? Solid answers, keep them. If not, let’s talk.
What happens on the strategy call
What we cover
Where you are today and where you want to be in 12 months. Your treatments, states and timeline. What is already working and what is leaking. The path we would take, in order, and whether we are the right team for it. If we are not, we will tell you who is.
What to bring
Your treatment list and target states. Current numbers if you are live (ad spend, new patients, refill rate). The platforms or vendors you are considering. Rough is fine.
About cost: Every launch is scoped to your states, product mix and goals, so we put real numbers in front of you on the call.
Book a strategy callYou’ll leave with a claim-by-claim read of your current GLP-1 ads and site against the 2026 warning letters, plus a channel and retention plan for your states.
FAQ
+Can you run Facebook ads for GLP-1 programs?
Yes, within Meta’s rules. Promoting prescription weight treatment on Facebook and Instagram requires LegitScript certification and Meta’s own approval. Meta’s health policies also ban before-and-after images and body-focused hooks, and weight-related ads must target adults 18 and over. Brands without certification face much tighter limits. We check your eligibility first, then build provider-led ads and landing pages that match.
+Do I need LegitScript to market a GLP-1 program?
For most GLP-1 brands, yes. LegitScript is the third-party certification Google and Meta check before they let a telehealth brand advertise prescription treatments, and many payment processors look for it too. Without it, Google Search on drug terms, Google Shopping and most prescription-focused Meta ads are off the table. Review runs on LegitScript’s timeline, so start early. Our LegitScript certification page walks through it.
+What should a GLP-1 patient cost to acquire?
In our accounts, cold new-patient CAC (what it costs to acquire one paying patient) for telehealth programs typically runs $150 to $350. Mature campaigns often land around $90 to $170, and we work toward $150 to $200. Patient lifetime value is often $2,000 to $3,000 or more when retention is built in. Results vary by offer, state mix, budget and execution. Past results do not guarantee future results.
+Can you market compounded semaglutide?
Yes, accurately. We describe it as a compounded medication prepared by a state-licensed 503A pharmacy for an individual prescription, and we identify the compounder where required. We never call it FDA-approved, generic, or the same as Ozempic or Wegovy. Your healthcare counsel signs off on every claim, and on whether your program should offer it at all, before anything runs.
+How fast can a new GLP-1 brand get patients?
Paid traffic can start once your site, compliance review and ad accounts are approved. Some approvals, like LegitScript, run on the certifier’s timeline, so no one can honestly promise a date. Meaningful organic traction typically takes 3 to 4 months. On the strategy call we map a realistic timeline for your states, your offer and where your approvals stand today.
Build a GLP-1 program patients stay in
Bring your current ads, site and offer, and we’ll show you what to keep, what to fix and where your next patients come from.
Get my GLP-1 growth planSources
ModFX Media is a marketing agency, not a medical provider, pharmacy or law firm. This page is educational and is not medical or legal advice. Whether a treatment is right for a patient is decided by a licensed provider, and availability depends on the medication and state rules.